Research Paper

Hydroxylase Activity of ASPH Promotes Hepatocellular Carcinoma Metastasis Through Epithelial-to-Mesenchymal Transition Pathway

Qifei Zou\textsuperscript{a,1}, Ying Hou\textsuperscript{a,b,1}, Haibo Wang\textsuperscript{a,1}, Kui Wang\textsuperscript{a}, Xianglei Xing\textsuperscript{a}, Yong Xia\textsuperscript{a}, Xuying Wang\textsuperscript{a}, Jun Li\textsuperscript{a}, Binghua Jiao\textsuperscript{c}, Jingfeng Liu\textsuperscript{d}, Aimin Huang\textsuperscript{d}, Dong Wu\textsuperscript{a}, Hongjun Xiang\textsuperscript{a}, Timothy M. Pawlik\textsuperscript{e}, Hongyang Wang\textsuperscript{f}, Wan Yee Lau\textsuperscript{a,g}, Yizheng Wang\textsuperscript{b,**}, Feng Shen\textsuperscript{a,**}

\textsuperscript{a} Department of Hepatic Surgery, The Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China
\textsuperscript{b} Laboratory of Neural Signal Transduction, Institute of Neuroscience, Chinese Academy of Science, Shanghai, China
\textsuperscript{c} Department of Biochemistry and Molecular Biology, Second Military Medical University, Shanghai, China
\textsuperscript{d} Department of Hepatobiliary Surgery, The Mengchao Hepatobiliary Surgery Hospital, Fujian Medical University, Fuzhou, China
\textsuperscript{e} Department of Surgery, The Ohio State University, Wexner Medical Center, Columbus, OH, USA
\textsuperscript{f} National Scientific Center for Liver Cancer, Shanghai, China
\textsuperscript{g} Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, SAR, China

A R T I C L E  I N F O

Article history:
Received 8 March 2018
Received in revised form 3 May 2018
Accepted 3 May 2018

Keywords:
ASPH
Hydroxylase
Hepatocellular carcinoma
Metastasis
Epithelial-mesenchymal transition
Vimentin

A B S T R A C T

Over-expression of aspartyl (asparagynal)-β-hydroxylase (ASPH) contributes to hepatocellular carcinoma (HCC) invasiveness, but the role of ASPH hydroxylase activity in this process remains to be defined. As such, the current study investigated the role of ASPH hydroxylase activity in downstream signalling of HCC tumorigenesis and, specifically, metastasis development. Over-expression of wild-type ASPH, but not a hydroxylase mutant, promoted HCC cell migration in vitro, as well as intrahepatic and distant metastases in vivo. The enhanced migration and epithelial to mesenchymal transition (EMT) activation was notably absent in response to hydroxylase activity blockade. Vimentin, a regulator of EMT, interacted with ASPH and likely mediated the effect of ASPH hydroxylase activity with cell migration. The enhanced hydroxylase activity in tumor tissues predicted worse prognoses of HCC patients. Collectively, the hydroxylase activity of ASPH affected HCC metastasis through interacting with vimentin and regulating EMT. As such, ASPH might be a promising therapeutic target of HCC.

© 2018 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Hepatocellular carcinoma (HCC) is the sixth most common malignancy and third leading cause of cancer-related mortality worldwide [1]. The overall prognosis of HCC patients remains poor due to its aggressive nature, including an invasive phenotype that is mediated by factors yet to be elucidated [2,3].

Aspartyl (asparagynal) β-hydroxylase (ASPH) is a member of the α-ketoglutarate-dependent dioxygenase family, which adds hydroxyl groups to β carbons of specific aspartate or asparagine residues in epidermal growth factor (EGF)-like domains [4,5]. In addition to full-length ASPH, the ASPH gene locus also encodes three additional truncated transcripts known as humbug, junctate and junction [6–8]. In particular, humbug transcription is driven by the same promoter of ASPH transcripts and utilizes common exons and open reading frames, whereas chooses an alternative and premature 3′ terminal exon that results in lacking the catalytic domain in the C-terminus of ASPH [6,8,9]. This unusual form of exon sharing between ASPH and humbug may suggest that their functions are highly linked.

ASPH has been reported to be one of the most up-regulated genes in HCC and its over-expression in tumor tissues has been associated with aggressive clinicopathological features and decreased survival [10–12]. However, the exact function of ASPH expressed in tumor tissues has not been clearly defined. Evidence based on isoform-specific methods used to investigate the function of ASPH have been limited. The established prognostic role of ASPH was based on immunostaining using antibodies that were raised from N-terminal peptide of ASPH, which predictably recognized humbug as well [13–15]. Moreover, the conventional gain- or loss-of-function assay of ASPH did not rule out the possible involvement of the non-catalytic domain of humbug being independent of the hydroxylase activity [16–18]. In addition, the functions of ASPH hydroxylase...
activity remain unclear, as structural and biochemical studies have failed to define any functional consequence of hydroxylated factor IX and X, known as the substrates of ASPH [19–21]. Recent study has also demonstrated that humbug itself may exert a potential oncogenic role, as observed in gastric and colon cancers2s [22,23]. Therefore, it remains unclear whether ASPH promotes HCC progression through its hydroxylase activity or non-catalytic domains of humbug. Accordingly, the downstream signalling involved in this process have yet to be determined.

The current study sought to investigate the impact of ASPH hydroxylase activity on HCC invasiveness and metastatic potential. The hydroxylase downstream molecular mechanism and the prognostic impact of the ASPH hydroxylase activity were also defined.

2. Materials and Methods

2.1. Cell Lines, Constructs and Primers

Human embryonic kidney 293 cells, and human HCC cell lines that included Huh-7, SMMC-7721, MHCC-97L and EHBC-512, were maintained as previously described [24]. The ASPH coding sequence was amplified from a cDNA library of EHBC-512. The enzymatic loss ASPH mutant was prepared through site mutagenesis of histidine-679, a reported essential residue for ASPH catalytic activities [19,23], to alanine using an in vitro mutagenesis system (Promega, Madison, WI). The coding sequence of vimentin was synthesized by Shanghai GenePharma (Shanghai, China). The shRNA sequences for silencing ASPH and vimentin were 5′-GCGCAGTGAGGATGAT-3′ and 5′-GCTAACTACCAAGACACTATT-3′, respectively. The lentivirus of vimentin, wild-type (WT) or mutant ASPH and the shRNA against human ASPH or vimentin were constructed, packaged and harvested by Shanghai GenePharma. The FLAG-ASPH and HA-vimentin plasmids were constructed through the introduction of ASPH and vimentin coding sequence into pFLAG-CMV (Sigma, St. Louis, MO) and pCMV-HA vectors (Clontech, Kusatsu, Shiga Japan). The primers are listed in Table S1.

2.2. Immunostaining and Immunoblot

These experiments were performed as previously described [24]. The polyclonal antibody of ASPH (FE1) was made in our institution using the synthetic peptide antigen of 12 amino acid residues around the Fe2+−binding domain of ASPH. Anti-ASPH (14116-1-AP) (Proteintech) against N-terminal of ASPH, anti-GFP tag (7G9) (M20004) and anti-actin (M25063) (Ambart, Shanghai, China), anti-myc (sc-40) (Santa Cruz, Dallas, TX), anti-E-cadherin (#610404)(BD Biosciences, San Jose, CA), anti-α-catenin(#2131) and anti-β-catenin (#2309) (Cell Signalling, Danvers, MA), anti-β-catenin(ab8978) (Abcam, Cambridge,UK), anti-β-catenin (bs-1165R), anti-Acryx1 (bs-24939R) and anti-NICD (bs-1335R) (Bios, Shanghai, China) antibodies were used for western blot or immunostaining. These experiments were performed as previously described [24]. The enzymatic loss ASPH mutant was prepared through site mutagenesis of histidine-679, a reported essential residue for ASPH catalytic activities [19,23], to alanine using an in vitro mutagenesis system (Promega, Madison, WI). The coding sequence of vimentin was synthesized by Shanghai GenePharma (Shanghai, China). The shRNA sequences for silencing ASPH and vimentin were 5′-GCGCAGTGAGGATGAT-3′ and 5′-GCTAACTACCAAGACACTATT-3′, respectively. The lentivirus of vimentin, wild-type (WT) or mutant ASPH and the shRNA against human ASPH or vimentin were constructed, packaged and harvested by Shanghai GenePharma. The FLAG-ASPH and HA-vimentin plasmids were constructed through the introduction of ASPH and vimentin coding sequence into pFLAG-CMV (Sigma, St. Louis, MO) and pCMV-HA vectors (Clontech, Kusatsu, Shiga Japan). The primers are listed in Table S1.

2.3. Asp β-Hydroxylation Assay In Vitro

This assay was modified from previously described methods [19,21]. The first EGF-like domain of human factor IX (China Pectides, Hangzhou, China) was used as the substrate for ASPH. Enzymes were prepared from dialyzed cell lysates of 293 cells transfected with WT-ASPH or H679A. The reaction mixture was incubated in a final volume of 50 μl at 37 °C for 30 min, containing 50 mM Pipes, pH 7.0, 100 mM Fe2+, 20 mM alpha ketoglutarate (α-KG), 0.1 mg/ml BSA, and 100 mM substrate. The α-KG concentration was measured before and after the reaction using the α-KG assay kit (Biovision, Milpitas, CA) according to the manufacturer’s instruct. The α-KG consumption reflected hydroxylase activity, which was calculated and calibrated without the substrate. All assays were measured in triplicate and repeated at least three times.

2.4. Cell Growth Curve, Cell Cycle, Cell Migration and Cell-Matrix Adhesion Assay

Cell growth curve, cell cycle and cell migration were assayed as previously described [24]. Cell-matrix adhesion assay was carried out in a 96-well-plate. Briefly, 50 μl of tumor cells with a dilution of 4 × 105/ml were added to each well of the 96-well-plate precoated with Matrigel (BD Bioscience). After incubation at 37 °C for 30 min, unattached cells were washed off and cells adhered to the surface were fixed with 4% paraformaldehyde and then stained with crystal violet. After the plate was washed and dried, the crystal violet was dissolved with 40% acetic acid. The absorbance at 550 nm read by spectrophotometer (Molecular Device, Sunnyvale, CA) was used as an index of cell-matrix adhesion capability. Each sample was assayed and measured in triplicate, and all experiments were repeated at least three times.

2.5. HCC Metastasis Model in Nude Mice

Four-week old male BALB/c nude mice were maintained and cared for according to institutional guidelines. The intrahepatic and distant lung metastasis animal models were established as previously described [2010; [24]]. Briefly, in the intrahepatic metastasis model, a total of 1 × 106 Huh-7 cells stably transfected with different constructs were injected into the mice in one left lobe of the liver. Animals were sacrificed 3 months after implantation. Intrahepatic metastases were diagnosed by visible tumor nodules on the opposite liver lobe without cell injection. In the lung metastasis model, a total of 1 × 106 MHCC-97L cells stably transfected with different constructs were injected subcutaneously. Animals were sacrificed 3 months after implantation. Lung metastases were diagnosed through visual inspection and confirmed by histological staining. Livers and lungs were excised. The tissue samples were fixed and embedded in paraffin. Paraffin sections were stained with haematoxylin–eosin (H&E) and vimentin for histological examination.

2.6. Pull-Down Assay, Mass Spectrometry and Co-Immunoprecipitation

FLAG-ASPH and HA-vimentin plasmids were transfected into 293 cells. Crude cell lysate was prepared 72 h after transfection. The protein complex interacting with FLAG-ASPH and HA-vimentin was obtained from a cDNA library of EHBC-512. The enzymatic loss ASPH mutant was prepared through site mutagenesis of histidine-679, a reported essential residue for ASPH catalytic activities [19,23], to alanine using an in vitro mutagenesis system (Promega, Madison, WI). The coding sequence of vimentin was synthesized by Shanghai GenePharma (Shanghai, China). The shRNA sequences for silencing ASPH and vimentin were 5′-GCGCAGTGAGGATGAT-3′ and 5′-GCTAACTACCAAGACACTATT-3′, respectively. The lentivirus of vimentin, wild-type (WT) or mutant ASPH and the shRNA against human ASPH or vimentin were constructed, packaged and harvested by Shanghai GenePharma. The FLAG-ASPH and HA-vimentin plasmids were constructed through the introduction of ASPH and vimentin coding sequence into pFLAG-CMV (Sigma, St. Louis, MO) and pCMV-HA vectors (Clontech, Kusatsu, Shiga Japan). The primers are listed in Table S1.

2.7. Prognostic Significance of ASPH Hydroxylase Activity

A training cohort of patients (n = 213) who underwent liver resection for histologically proven HCC at the Eastern Hepatobiliary Surgery Hospital (EHBB) between 2004 and 2008 and a validation cohort of patients (n = 103) operated at the Mengchao Hepatobiliary Surgery Hospital (MHHB) between 2002 and 2008 were used. Inclusion criteria: (i) had grade 0 or 1 of Eastern Cooperative Oncology Group (ECOG) performance status; (ii) had Child-Pugh class A of liver function; (iii) did not have major hepatic portal
vein tumor thrombus and distant metastasis; and (iv) underwent a R0 liver resection for HCC. Patients who met the criteria were included for prognostic analyses. The clinicopathologic data of all enrolled patients was prospectively collected and maintained in our database. This study was approved by the Institutional Ethics Committees of both centers. Informed consent to use patient data and resected specimens for the purposes of research was obtained from all patients.

The specimen sections were stratified according to the percentages of ASPH positive tumor cells stained with FE1 antibody. Specifically, we defined <10% of FE1 staining positive cells as weak and >10% as intense, suggesting a low and high hydroxylase activity of ASPH, respectively. Histopathological diagnosis and IHC score were carried out independently by three pathologists; disagreements in scoring were adjudicated through discussion among the group.

After surgery, all patients were followed-up regularly once every 2 months within the first 2 years and then once every 3–6 months. The related information of clinical observation is detailed in Tables S6 and S7. At each visit, patients were checked with serum AFP and liver function tests, and abdominal ultrasound. A contrast-enhanced CT or MRI was performed once every 6 months or earlier when clinically indicated. Tumor recurrence was defined by the typical hallmarks of HCC on at least two imaging studies. The HCC recurrence was treated with multimodality options based on general performance, tumor stage, tumor location and cirrhosis. Primary endpoints were overall survival.

Fig. 1. ASPH hydroxylase activity is required for HCC cell migration and adhesion. (a) Validation of enforced expression of ASPH (wild-type) and its enzymatic mutant (H679A) in MHCC-97L, EHBC-512 and Huh-7 blotted by ASPH antibody specific for C-terminus. endo-ASPH, the lower band around 120kD is the endogenously expressed ASPH; exo-ASPH, the upper band is the exogenously expressed ASPH that is fused by a GFP tag. (b) The ASPH hydroxylase activity of wild-type and enzymatic mutant of ASPH measured by α-ketoglutarate (α-KG) consumption in in vitro Asp/Asn β-hydroxylation assay in 293 cells transfected with indicated construct. (c) The statistical results of cell migration of MHCC-97L, EHBC-512 and Huh-7 transfected with indicated constructs. (d) The statistical results of MHCC-97L, EHBC-512 and Huh-7 cell migration upon administration of hydroxylase inhibitor DIPY (1 μM) and DMOG (100 nM). (e) The statistical results of cell adhesion of MHCC-97L, EHBC-512 and Huh-7 transfected with indicated constructs. (f) The silencing of ASPH in MHCC-97L and EHBC-512 cells by lentivirus mediated shRNA (sh-1 and sh-2) that is testified by immunoblot. The relative quantification of blotting results was shown below. Effective RNAi constructs of sh-2 were used for later studies. (g) and (h) The statistical results of cell migration or cell adhesion for MHCC-97L and EHBC-512 cells transfected with indicated constructs in the transwell or cell adhesion assay, respectively. All data are shown as average ± SD based on at least three independent experiments after normalization to the control group. *P < 0.05, **P < 0.01 vs. control. Abbreviations: ctl or sh-ctl, vector only control group; WT, wild-type of ASPH; H679A, enzymatic mutant of ASPH.
Fig. 2. Blockade of cell migration by a novel antibody FE1 that targets the catalytic domain of ASPH. (a) Validation of the specificity of FE1 by the immunoblot. Upper: the peptide competition assay using EHBC-512 and MHCC-97L cell lysate in which FE1 were pre-incubated with the antigen peptide before used in immunoblot. Bottom: the specific recognition to wild-type but not enzymatic mutant of ASPH by FE1 using MHCC-97L transfected by indicated constructs. Endo-ASPH, the endogenously expressed ASPH; exo-ASPH, the exogenously expressed ASPH that was fused by a GFP tag. (b) Validation of the specificity of FE1 by the immunostaining. Co-localization of positive signal stained by FE1 and anti-GFP antibodies in Huh-7 cells over-expressed with GFP-tagged ASPH (400×). (c) Cell surface expression of ASPH. Upper: immunostaining of ASPH by FE1 in impermeable EHBC-512 and MHCC-97L cells without triton X-100 treatment. The cell morphology was characterized by F-actin presence through phalloidin staining. Bottom: the presence of cell subsets with membrane or intracellular ASPH expression in EHBC-512 and MHCC-97L cells with or without triton X-100 treatment measured by flow cytometers. (d) The ASPH hydroxylase activity in 293 cells transfected with ASPH upon administrating 100 μg/ml of FE1 antibody or isotype IgG measured by α-ketoglutarate (α-KG) consumption in in vitro Asp/Asn β-hydroxylation assay. (e) and (f) The statistical results of cell migration in Huh-7 cells transfected with indicated constructs, EHBC-512 and MHCC-97L cells that were treated by 100 μg/ml of FE1 antibody or isotype IgG, otherwise the FE1 concentration was designated. All data are shown as average ± SD based on at least three independent experiments after normalization to the control group. *P < 0.05, **P < 0.01 vs. IgG treatment. Abbreviations: ctl, vector only control group; WT, wild type of ASPH; H679A, enzymatic mutant of ASPH.
dedefined as the interval between the date of surgery and the date of patient death or last follow-up; other endpoints included time to recurrence (TTR), which was the interval between the date of surgery and the date of diagnosis of HCC recurrence. The follow-up was censored on June 2012.

2.8. Statistical Analysis

Statistical analyses were performed as previously described [12,24]. Statistical analyses were performed using SPSS (version 18.0, Chicago, IL). Continuous variables were expressed as mean ± SD or SEM, or as average ± SD based on at least three independent experiments after normalization to the control group. *P < 0.05, **P < 0.01 vs. control. Abbreviations: ctl, vector only control group; WT, wild type of ASPH; H679A, enzymatic mutant of ASPH.
indicated. Quantitative values were compared using the Mann-Whitney nonparametric $U$ test or Kruskal-Wallis test. Categorical variables were reported as the number of cases and the prevalence, and differences between the groups were compared using the $\chi^2$ test with Yates correction or Fisher exact test as appropriate. The OS and TTR were analyzed using the Kaplan-Meier method and the log-rank test. Independent risk factors were identified using the Cox proportional hazard model. A $p < 0.05$ was considered statistically significant.
3. Results

3.1. Hydroxylase Activity of ASPH is Required for HCC Migration

The WT and enzymatic mutant (H679A) of ASPH were constructed and transfected into human HCC cell lines MHCC-97L, EHB-C512 and Huh-7 (Figs. 1a and S1). In the enzymatic assay for Asp β-hydroxylation, cell lysates from H679A displayed less α-KG consumption than those cells with WT transfection, suggesting a reduced hydroxylase activity of the mutant. In fact, there was up to 76% (148-195) blockade of hydroxylase activity in H679A compared with WT-ASPH (Fig. 1b).

The impact of enhanced ASPH hydroxylase activity on cell growth, cell cycle progression, cell migration and cell adhesion in these transfected HCC cell lines was determined. Over-expression of WT-ASPH, but not H679A, enhanced cell migration in the transwell assay (Figs. 1c and S2a). In contrast, blockade of ASPH activity by 2,3-dipyridyl (DIPY) and dimethylglyoxal (DMOG), two inhibitors of hydroxylase, decreased cell migration (Fig. 1d). In addition, only HCC cells with enforced expression of WT-ASPH demonstrated enhanced cell adhesion (Fig. 1e) compared with cells transfected with control vector or H679A in EHB-C512 and Huh-7 cell lines.

EHB-C512 and MHCC-97L, which had endogenous ASPH expression, were used to selectively silence ASPH (Fig. 1f). Effective depletion of ASPH through shRNA also inhibited HCC cell migration (Figs. 1g and S2b) and cell-matrix adhesion (Fig. 1h). Of note, cell growth and cell cycle profile were unaffected by the change of ASPH expression level (Fig. S3a and b).

3.2. Specific Blockade of ASPH Hydroxylase Inhibits HCC Cell Migration

A polyclonal antibody (FE1) against the Fe-binding His-2 motif at the C-terminal of ASPH, a key region for hydroxylase activity, was prepared. As noted in Fig. 2a upper, FE1 specifically recognized endogenous ASPH in EHB-C512 and MHCC-97L, which were sensitive to antigen peptide competition. Unlike other antibodies targeting N-terminal of ASPH (Proteintech, Rosemont, IL), FE1 only recognized the WT-ASPH, but not the enzymatic mutant of ASPH (Fig. 2a lower). Co-immunostaining results demonstrated co-localization of FE1 positive signal and GFP fluorescence that was fused to exogenous ASPH (Fig. 2b).

Given previous reports that ASPH might translocate to the cell membrane in malignant cells [13,16], we performed cell surface ASPHimmunostaining in which permeabilizing cells by triton X-100 were omitted. Only EHB-C512 cells showed a clear membrane ASPH presence, whereas MHCC-97L cells did not (Fig. 2c upper). The flow cytometer analysis also demonstrated that a certain amount of EHB-C512 cells expressed ASPH on its cell surface, although nearly all EHB-C512 and an MHCC-97L cells intracellularly expressed ASPH (Fig. 2c lower).

In addition to its high specificity to ASPH, FE1 also greatly decreased α-KG consumption in the enzymatic assay for Asp β-hydroxylation compared with the IgG isotype control (Fig. 2d), suggesting the antibody was capable of neutralizing the hydroxylase activity of ASPH. The effect of this catalytically inhibitory antibody on migration of tumor cells with membrane ASPH expression was then examined. FE1 displayed a dose-dependent inhibitory effect on cell migration in Huh-7 cells that had over-expression of WT-ASPH (Figs. 2e and S2c). The IC50 of FE1 was around 100 μg/ml, resulting in 80% enzymatic inhibition in the hydroxylase activity assay (Fig. 2d). Of note, FE1 did not block cell migration in Huh-7 cells over-expressed with H679A (Fig. 2e). Likewise, FE1 did inhibit cell migration in EHB-C512 cells that were positive for membrane ASPH in a dose-dependent manner, but was ineffective in MHCC-97L cells with low level of membrane ASPH (Fig. 2f).

3.3. Hydroxylase Activity of ASPH Promotes the Epithelial-to-Mesenchymal Transition

A gene co-expression analysis was performed to search for genes demonstrating a similar expression pattern with ASPH across HCC samples using previously prepared microarray and bioinformatics methodologies [10,26]. The down-regulation of CDH1 (E-cadherin) and RGS2 levels, and up-regulation of TIMP1, ITGB1 and COL1A2 levels were associated with enhanced ASPH levels, implying that the occurrence of epithelial-to-mesenchymal transition (EMT) was connected with ASPH over-expression (Fig. S4).

To better understand the relation between EMT signalling activation and ASPH hydroxylase activity, we examined the change of mRNA expression of EMT biomarkers and regulatory genes through a PCR array using EHB-C512 cells that either had ASPH over-expressed, silenced or mutated compared with control cells, respectively. As noted in Fig. 3a, ASPH over-expression in EHB-C512 cells induced up-regulation of genes that promote EMT, while simultaneously causing down-regulation of genes that inhibit EMT. However, over-expressing H679A did not affect mRNA expression of those EMT-related genes. Moreover, silencing ASPH conferred an opposite effect compared with EMT-related gene expression as did ASPH over-expression. The result of the PCR array was further validated using real-time PCR, which again confirmed that the ASPH activity regulated gene expression profile was associated with EMT (Fig. 3b).

The activation of EMT signalling by enhanced ASPH hydroxylase activity was also verified in Huh-7 cells using immunostaining and immunoblot techniques. These experiments demonstrated that Huh-7 cells over-expressed with WT-ASPH, but not mutant H679A, diminished expression of epithelial cell markers including γ-catenin, α-catenin and E-cadherin, while enhancing expression of vimentin, a mesenchymal marker compared with control constructs (Fig. 3c and d). It has been reported that Wnt-β-catenin pathway plays significant role in EMT [27]. Our data showed that over-expression of WT-ASPH, but not H679A mutant, diminished the mRNA and protein levels of AXIN1, a negative regulator of Wnt-β-catenin pathway in Huh-7 cells, while enhanced the protein level of β-catenin (Fig. S5a and b), as well as RNA level of β-catenin (Fig. 3b).

Previous reports had suggested that the notch pathway might be the putative downstream signalling of ASPH [16,28,29]. Consistent with these findings, we similarly noted that ASPH over-expression in EHB-C512 cells induced an increased mRNA level of notch pathway (Fig. 3e). However, over-expressing H679A also enhanced mRNA levels of Notch1, Hes1 and Jag1 compared with the control group (Fig. 3e). In addition, ASPH over-expression in EHB-C512 cells slightly enhanced Notch 1 intracellular domain (NICTD) nuclear translocation compared with control and H679A (Fig. S6).

Fig. 4. The role of ASPH-vimentin interaction in promoting HCC cell migration. (a) and (b) Identification of exogenous ASPH-vimentin interaction. Left: The base-peak plot of mass spectrometry analysis of protein complex from pull-down assay in 293 cells over-expressed with FLAG-fusion ASPH or HA-fusion vimentin using protein tag antibodies. Right: identified peptide sequence belonging to vimentin and ASPH in the protein complex. (c) Validation of endogenous ASPH-vimentin interaction. The immunoblot (IB) of the protein immuno-precipitated (IP) with FE1 and anti-vimentin in MHCC-97 cells. (d) Validation of manipulated vimentin expression in MHCC-97L and Huh-7 cells. Left: complementary over-expression of vimentin control and ASPH-silenced MHCC-97L cells. Right: complementary silencing vimentin in control and ASPH-over-expressed Huh-7 cells. The relative quantification of blotting results is shown below. (e) The indispensable role of vimentin for ASPH in regulating cell migration. Left: functional blockade of cell migration by silencing vimentin in ASPH-over-expressed Huh-7 cells. Right: functional rescue cell migration by over-expressing vimentin in ASPH-silenced in MHCC-97L cells. (f) Effect of hydroxylase inhibition to vimentin-dependent cell migration. Left y axis: the statistical results of cell migration in vimentin-over-expressed MHCC-97L cells that is treated by DIPY (1 μM) and DMOG (100 nM), right y axis: the corresponding increased fold of cell migration by vimentin over-expression in comparison to control group. All data are shown as average ± SD based on at least three independent experiments after normalization to the control group. *P < 0.05, **P < 0.01 vs. control. Abbreviations: ctrl or sh-ctl, vector only control group; WT, wild type of ASPH; VIM: vimentin; sh-ASPH, ASPH silencing; sh-VIM, vimentin silencing.
3.4. ASPH Interacts with Vimentin to Promote HCC Cell Migration

For identifying the direct downstream molecule of ASPH, we performed the pull-down assay to obtain the protein complex interacting with ASPH over-expressed with FLAG tagged-ASPH using 293 cells as a modelling cell mainly due to its high transfection efficiency and low endogenous expression of ASPH. In mass spectrometry, vimentin peptides could be detected in the protein complex precipitated by anti-
Flag antibodies (Fig. 4a). In addition, the presence of ASPH peptides in the protein complex was also observed from the pull-down assay of HA tagged-vimentin (Fig. 4b). The interaction between endogenous ASPH and vimentin was further identified by reciprocal immunoprecipitation and immunoblot by vimentin and ASPH antibodies, respectively, in MHCC-97L cells (Fig. 4c).

For evaluating the mediator effect of vimentin for ASPH, we sequentially over-expressed or silenced ASPH and vimentin in HCC cells based on the cell’s established ASPH expression status, showing that over-expression of ASPH enhanced the expression of vimentin and vice versa, and down-regulation of ASPH slightly decreased the expression of vimentin (Fig. 4d). In Fig. 4e, over-expression of vimentin itself greatly promoted HCC cell migration, while knockdown of vimentin exerted an inhibitory effect. In particular, over-expression of vimentin effective-ly reversed the inhibitory effect of cell migration caused by knockdown of ASPH. Also, tumor cells over-expressed with ASPH failed to display any enhancement of cell migration after vimentin was selectively silenced.

In order to test the relationship between ASPH hydroxylase activity and vimentin function, we analyzed the effect of the hydroxylase inhibitors, DIPy and DMOG, on vimentin-dependent promotion of cell migra-tion. As noted in Fig. 4f, enzymatic blockade of ASPH did not completely eliminate, but indeed weaken the extent of enhancement of cell migration in MHCC-97L cells induced by enforced expression of vimentin, suggesting that ASPH hydroxylase activity might affect vimentin function.

3.5. Hydroxylase Activity of ASPH Is Required for HCC Metastasis In Vivo

The metastatic capability of the different HCC cell lines and the num-ber of generated metastatic nodules are summarized in Table S2. In an-imal models with intrahepatic metastasis, Huh-7 cells that had over-expression of WT-ASPH had a higher probability of intrahepatic metastasis (17/25) and more metastatic nodules (25) in transplanted mice compared with H679A (22/25 and 2, respectively) and control vectors (0/25 and 0, respectively) (Fig. 5a and b). However, there was no obvi-ous difference in the primary tumor size that was formed by Huh-7 cells over-expressing WT-ASPH, H679A, and control vectors on histological examination (Fig. 5a and c); of note, some aggressive pathological fea-tures such as microsatellite lesion formation and stromal infiltration were, however, only observed in the WT-ASPH group (Fig. 5c). Consistent with our in vitro findings, only over-expression of WT-ASPH pro-moted vimentin expression in tumor tissues compared with control and H679A (Fig. 5c). In addition, immunostaining with FE1 and anti-vimentin showed that the intense ASPH staining was well correlated with the intense vimentin staining in HCC tissues from surgical speci-mens (Fig. S7).

In animal models with lung metastasis, silencing ASPH in MHCC-97L cells decreased the probability of distant metastasis (3/25) and resulted in less lung metastatic nodules (3) compared with the nonsense control group that had high endogenous ASPH expression (2/25 and 0, respectively) (Fig. 5d and e). In particular, lung metastatic lesions formed by MHCC-97L cells demonstrated a clear EMT characteristic in terms of vimentin expression which was significantly lost after ASPH was selec-tively silenced (Fig. 5d).

3.6. Enhanced ASPH Hydroxylase Activity Is Associated With a Poor Prognosis

Using FE1 immunostaining, the tumoral ASPH hydroxylase activity was tested (Table S3). The staining intensity was differentially up-regulated in tumor (intense vs. weak: 122 patients, 57.3% (122/213) vs. 91 patients, 42.7% (91/213) versus non-tumor (80, 37.6% (80/213) vs. 133, 62.4% (133/213), P = 0.01) tissues in the training cohort (Figs. 6a and Table S4); these findings were confirmed in the validation cohort.

In the training cohort, there was also a significant association be-tween enhanced ASPH hydroxylase activity and higher serum alpha-fetoprotein (AFP) level, larger tumor size, multiple nodules, microvas-cular invasion, and late tumor stages according to the Barcelona Clinic Liver Cancer (BCLC) system (P = 0.038) and the TNM system (Table S5). Patients with increased ASPH hydroxylase activity had a higher incidence of recurrence at 5-years (78.6% vs. 48.4% for the in-tense and weak FE1 signalling groups respectively), as well as a lower 5-year OS (35.8% vs. 55.8%) compared with patients who had tumors with low ASPH hydroxylase activity (Fig. 6b). For patients with early stage HCC defined as BCLC stage 0/A, an increased hydroxylase activity also predicted a poor prognosis (5-year recurrence: 61.0% vs. 40.4%; 5-year OS: 42.4% vs. 68.2%, for the intense and weak FE1 signalling groups respectively) (Fig. 6b). Again, these results were validated in the valida-tion cohort (Fig. 6c).

Univariable and multivariable analyses demonstrated that the in-tensity of FE1 staining was an independent risk factor for both tumor recurrence and OS in the training cohort (hazard ratio: 1.619, 95% confidence interval: 1.109–2.363; 1.987, 1.252–2.129), as well as the validation cohort (1.838, 1.033–3.271; 2.608, 1.121–3.817) (Tables S6 and S7).

4. Discussion

In this study, we defined and characterized the important role that the hydroxylase activity of ASPH plays in HCC metastasis in vitro and in vivo. Particularly, this role has been demonstrated in nude mice with intrahepatic and distant metastases of HCC. Specifically, the inter-action between the hydroxylase activity and vimentin regulated EMT in HCC cell lines. In addition, enhanced ASPH hydroxylase activity in HCC tissues was closely associated with aggressive clinicopathological fea-tures and a decreased survival outcome.

To date, understanding the biological function of post-translational modification of β-hydroxyasparaginyl/β-hydroxyaspartyl has been very limited [6,20]. Although the role of ASPH had been demonstrated in some human malignancies [13,14,30–33], the biological conse-quences of ASPH hydroxylase activity had remained much less clear. In the current study, we utilized enzymatic mutant analysis and performed single site mutagenesis (H679A) of a highly conserved and es-sential histidine within the enzymatic domain of ASPH and demonstrated up to a 76% blockade of hydroxylase activity based on an enzymatic assay. In comparing the invasive and metastatic ability of HCC cell lines that were over-expressed with WT or H679A mutant ASPH, we demonstrated that only over-expression of ASPH with intact hydroxylase activity promoted HCC cell migration in vitro, as well as...
tumor intrahepatic and distant lung metastases in vivo. The data demonstrated the essential role of ASPH hydroxylase activity in facilitating invasiveness and metastasis in human malignancies such as HCC in vivo. Consistent with our findings, the small molecule inhibitor MO-I-1100, which reduces ASPH hydroxylase activity, was recently developed and shown to have an anti-tumor effect [10].

Collectively, based on the data, we proposed EMT as a downstream signalling pathway of ASPH hydroxylase activity in HCC. EMT could be...
induced by enhanced hydroxylase activity in HCC cells, which is absent from cells transfected with ASPH enzymatic mutant. Furthermore, vimentin was identified as a new interaction partner of ASPH, providing a mechanistic connection between ASPH and EMT. Over-expression of vimentin is associated with HCC development and metastasis [34]. To this point, data from the current study demonstrated that vimentin was critical for cell migration promoted by ASPH hydroxylase activity in the functional complementary assays. Although the direct hydroxylation of vimentin by ASPH needs to be confirmed, results from the current study demonstrated that the enhancement of cell migration through over-expressing vimentin was sensitive to hydroxylase inhibitors, suggesting the importance of ASPH hydroxylase activity in vimentin signalling.

Previous studies have suggested that HIF-1α-ASPH-Notch axis was involved in cell motility regulation [29]. Our data also confirmed that Notch pathway activation, in terms of enhanced mRNA level of Hes1 and Notch1 and nuclear translocation of Notch1, was in response to the enhanced expression of ASPH. Nevertheless, we cannot exclude the potential involvement of HIF-1α as an upstream regulator of ASPH in HCCs.

In earlier clinical studies of ASPH, its expression was mainly assessed by immunostaining using antibodies, which had a high probability of cross-reaction with the non-catalytic humbug given that these antibodies had a higher affinity to humbug rather than ASPH given its C-terminus with hydroxylase activity [12–14,23,32,33]. As such, we made an antibody (FE1) specific for the essential motif within the catalytic domain of ASPH. This antibody had extremely high specificity for ASPH with intact hydroxylase activity, as demonstrated by its not recognizing the H679A mutant. By using FE1 to assess data from a multicentric database, we were able to validate that an increased ASPH hydroxylase activity in HCC tissue contributed to a markedly worse long-term prognosis following curative resection for HCC.

In addition to the lack of cross-reaction with humbug, the FE1 antibody displayed some other distinct advantages. First, the FE1 antibody directly recognized ASPH in the plasma membrane without permeabilizing cells. Second, the antibody could neutralize ASPH hydroxylase activity, which likely resulted from its specific binding to the central motif of the catalytic domain of ASPH [19,25]. Third, FE1 inhibited cell migration through targeting membrane ASPH. The therapeutic potential of ASPH, especially the surface expressed isoform, has been recently confirmed in several studies [10,35–39]. This is not surprising as most predicted ASPH substrates are extracellular matrix (ECM) proteins [40,41] and membrane ASPH sheds its catalytic domain outside of the membrane, facilitating the hydroxylation of ECM by ASPH. Although vimentin is an intracellular protein, it is actually connected to a complicated ECM network through a physical interaction [42–44]. The interaction between ASPH and vimentin provided a possibility that ECM might relay the inhibitory signal upon FE1 binding to surface ASPH to regulate the vimentin function.

One limitation of the current study was that we failed to identify the hydroxylated residues mainly due to technical limitation in detecting [δ-hydroxyasparaginyl]-δ-hydroxyaspartyl on the protein. Further study is required to address this shortcoming.

In summary, data from the current study demonstrated the crucial role of ASPH hydroxylase activity in HCC invasiveness and metastatic potential. ASPH hydroxylase activity regulates EMT pathway likely through interacting with vimentin.

Acknowledgements
Not applicable.

Funding Sources
This study was supported by the State Key Project for Research of Infectious Diseases (2012ZX10002-016), the 973 Program (2006CB806600), the Creative Research Groups of National Natural Science Foundation of China (30921006), the Shanghai Municipal Science and Technology Project (12431900803), the National Natural Science Foundation of China (81301828), and the project of Shanghai Hospital Development Center (SHDC12015104). These funding sources had no role in the study design, data collection, data analysis, interpretation, or writing of this manuscript.

Conflict of Interest Statement
The authors declare that they have no competing interests.

Author Contributions
F.S., Y.W., Q.Z. and Y.H. designed the research. Q.Z., Y.H., K.W., X.L., J.L. and B.J. performed the majority of the experiments. Y.X., W.Y., J.L., A.H. and D.W. provided clinical specimens and performed clinical observation. H.X., H.W. and W.Y.L assisted with study design and analyzed data. Q.Z., Y.H., H.W., T.M.P., Y.W. and F.S. conceived this study, wrote and revised the manuscript.

Appendix A. Supplementary Data
Supplementary data to this article can be found online at https://doi.org/10.1016/j.ebiom.2018.05.004.

References
[1] Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018;391:1301–14.
[2] Rahbari NN, Mehrabi A, Möllberg NM, Muller SA, Koch M, Buchler MW, et al. Hepato-cellular carcinoma: current management and perspectives for the future. Ann Surg 2011;253:453–60.
[3] Vauthney JN, Laweers GY, Saenula NT, Do KA, Belghiti J, mirza N, et al. Simplified stag-ing for hepatocellular carcinoma. J Clin Oncol 2002;20:1527–36.
[4] Jia S, Vandusen WJ, Deihl RE, Koli NE, Dixon RA, Elliott KO, et al. DNA cloning and expression of bovine asparagine (asparaginyl) beta-hydroxylase. J Biol Chem 1992;267:14322–7.
[5] Monkovic DD, Vandusen WJ, Petroski CJ, Garsky VM, Sardana MK, Zawodzsky P, et al. Invertebrate asparagine/asparaginyl beta-hydroxylase: potential modification of eucaryo-genous epidermal growth factor-like modules. Biochem Biophys Res Commun 1992;189:233–41.
[6] Dinchuk JE, Henderson NL, Burn TC, Huber R, Ho SP, Link J, et al. Aspartyl beta–hydroxylase (Asph) and an evolutionarily conserved isoform of Asph missing the catalytic domain share exons with junctin. J Biol Chem 2000;275:3954–54.
[7] Ferlito G, Finotti A, Breveglieri G, Tresves S, Zorzato F, Gambari R. Multiple levels of control of the expression of the human A beta-H1-Jlocus encoding asparaginyl-beta-hydroxylase, the junctin, and junctate. Ann N Y Acad Sci 2006;1091:184–90.
[8] Ferlito G, Finotti A, Breveglieri G, Tresves S, Zorzato F, Gambari R. Transcriptional activity and Sp 1/s3 transcription factor binding to the PI promoter sequences of the human Abeta-H1-Jlocus, FEMS J 2007;274:4476–90.
[9] Lahousse SA, Carter JJ, Xu XJ, Wands JR, De La Monte SM. Differential growth factor regulation of asparagine-asparaginyl beta-hydroxylase family genes in SH-SY5Y human neuroblastoma cells. BMC Cell Biol 2006;7:41.
[10] Alhara A, Huang CK, Olsen MJ, Lin Q, Chung W, Tang Q, et al. A cell-surface beta-hydroxylase is a biomarker and therapeutic target for hepatocellular carcinoma. Hepatology 2014;60:1302–13.
[11] Tang C, Hou Y, Wang H, Wang X, Liang H, Wang X, et al. Aspartate beta-hydroxylase disrupts mitochondrial DNA stability and function in hepatocellular carcinoma. Oncogene 2017;36:3626–6.
[12] Wang K, Liu J, Yan ZL, Li J, Shi LH, Cong WM, et al. Overexpression of asparagine-asparaginyl-beta-hydroxylase in hepatocellular carcinoma is associated with worse surgical outcome. Hepatology 2010;52:164–73.
[13] Lavaisiere L, Jia S, Nishiyama M, De La Monte S, Stern AM, Wands JR, et al. Overexpression of human asparagine/asparaginyl-beta-hydroxylase in hepatocellular carcinoma and cholangiocarcinoma. J Clin Invest 1999;98:1313–23.
[14] Palumbo KS, Wands JR, Safran H, King T, Carlson RI, De La Monte SM. Human asparagine-asparaginyl beta-hydroxylase monoclonal antibodies: potential biomarkers for pancreatic carcinoma. Pancreas 2002;25:39–44.
[15] Xue T, Su J, Li H, Xue X. Evaluation of HAAH/humbug quantitative detection in the diagnosis of hepatocellular carcinoma. Oncol Rep 2015;33:329–37.
[16] De La Monte SM, Tamaki S, Cantarini MC, Ince N, Wiedmann M, Carter JJ, et al. Asparagine-asparaginyl-beta-hydroxylase regulates hepatocellular carcinoma invasiveness. J Hepatol 2006;44:971–83.
[17] Gundogan F, Bedoya A, Gilligan J, LAU E, Mark P, De Paepe ME, et al. siRNA inhibition of asparagine-asparaginyl beta-hydroxylase expression impairs cell motility, Notch sig-naling, and fetal growth. Pathol Res Pract 2011;207:545–53.
[18] Sepe PS, Lahousse SA, Gemelli B, Chang H, Maeda T, Wands JR, et al. Role of the aspartyl-asparaginyl-beta-hydroxylase gene in neuroblastoma cell motility. Lab Invest 2002;82:881–91.

[19] Jia S, McGinnis K, Vandenbos WJ, Burke CJ, Kuo A, Griffin PR, et al. A fully active catalytic domain of bovine aspartyl (asparaginyl) beta-hydroxylase expressed in Escherichia coli: characterization and evidence for the identification of an active-site region in vertebrate alpha-ketoglutarate-dependent dioxygenases. Proc Natl Acad Sci U S A 1994;91:7227–31.

[20] Lancaster DE, McDonough MA, Schofield CJ. Factor inhibiting hypoxia-inducible factor (FIH) and other asparaginyl hydroxylases. Biochem Soc Trans 2004;32:943–5.

[21] Sumnerhagen MS, Persson E, Dahlqvist I, Drakenberg T, Stenfors J, Mayhew M, et al. The effect of aspartate hydroxylation on calcium binding to epidermal growth factor-like modules in coagulation factors IX and X. J Biol Chem 1993;268:23339–44.

[22] Lee JH. Overexpression of humbug promotes malignant progression in human gastric cancer cells. Oncol Rep 2008;19:795–800.

[23] Wang J, De La Monte SM, Sabo E, Kethu S, Tavares R, Branda M, et al. Prognostic value of humbug gene overexpression in stage II colon cancer. Hum Pathol 2007;38:17–25.

[24] Hou Y, Zou Q, Ge R, Shen F, Wang Y. The critical role of CD133(+)CD44(+/high) tumor cells in hematogenous metastasis of liver cancers. Cell Res 2012;22:259–72.

[25] McGinnis K, Ku GM, Vandusen WJ, Fu J, Garsky V, Stern AM, et al. Site-directed mutagenesis of residues in a conserved region of bovine aspartyl (asparaginyl) beta-hydroxylase expressed in Escherichia coli: characterization and evidence for the identification of an active-site region in vertebrate alpha-ketoglutarate-dependent dioxygenases. Proc Natl Acad Sci U S A 1994;91:7227–31.

[26] Jupiter D, Chen H, Vanburen V. STARNET 2: a web-based tool for accelerating discovery of gene regulatory networks using microarray co-expression data. BMC Bioinform 2009;10:332.

[27] Mcginnis K, Ku GM, Vandusen WJ, Burke CJ, Kuo A, Griswold M, et al. A fully active catalytic domain of bovine aspartyl (asparaginyl) beta-hydroxylase expressed in Escherichia coli: characterization and evidence for the identification of an active-site region in vertebrate alpha-ketoglutarate-dependent dioxygenases. Proc Natl Acad Sci U S A 1994;91:7227–31.

[28] Cantarini MC, De La Monte SM, Pang M, Tong M, D’Errico A, Trevisani F, et al. Aspartyl-asparagyl beta hydroxylase, hypoxia-inducible factor-alpha and Notch cross-talk in regulating neuronal motility. Oxidative Med Cell Longev 2010;3:347–56.

[29] Ince N, De La Monte SM, Wands JR. Overexpression of human aspartyl (asparaginyl) beta-hydroxylase is associated with malignant transformation. Cancer Res 2000;60:1261–6.

[30] Iwagami Y, Huang CK, Olsen MJ, Thomas JM, Jang G, Kim M, et al. Aspartate beta-hydroxylase modulates cellular senescence through glycogen synthase kinase 3beta in hepatocellular carcinoma. Hepatology 2016;63:1213–26.

[31] Lawton M, Tong M, Hebeda N, Gao J, Thomas JM, Olsen M, et al. Aspartate-beta-hydroxylase (ASPH): a potential therapeutic target in human malignant gliomas. Helioyun 2016;2:e00203.

[32] Wang J, De La Monte SM, Sabo E, Kethu S, Tavares R, Branda M, et al. Prognostic value of humbug gene overexpression in stage II colon cancer. Hum Pathol 2007;38:17–25.

[33] Shimoda M, Tomimaru Y, Charpentier KP, Safran H, Carlson RI, Wands JR. Tumor progression-related transmembrane protein aspartate-beta-hydroxylase is a target for immunotherapy of hepatocellular carcinoma. J Hepatol 2012;56:1129–35.

[34] Mendez MG, Koijima S, Goldman RD. Vimentin induces changes in cell shape, motility, and adhesion during the epithelial to mesenchymal transition. PASEB J 2010;24:1838–51.

[35] Borgia DL, Gao JS, Tong M, De La Monte SM. Potential role of phosphorylation as a regulator of Aspartyl-(asparaginyl)-beta-hydroxylase: relevance to infiltrative spread of human hepatocellular carcinoma. Liver Cancer 2015;4:139–53.

[36] Huang CK, Iwagami Y, Aihara A, chung W, De La Monte S, Thomas JM, et al. Antitumor effects of second generation beta-hydroxylase inhibitors on cholangiocarcinoma development and progression. PLoS One 2016;11:e0150336.

[37] Noda T, Shimoda M, Ortiz V, Sirica AE, Wands JR. Immunization with aspartate-beta-hydroxylase-loaded dendritic cells produces antitumor effects in a rat model of intrahepatic cholangiocarcinoma. Hepatology 2012;55:86–97.

[38] Sturla LM, Tong M, Hebeda N, Gao J, Thomas JM, Olsen M, et al. Aspartate-beta-hydroxylase (ASPH): a potential therapeutic target in human malignant gliomas. J Neurooncology 2016;126:1–10.

[39] Tomimaru Y, Mishra S, Safran H, Charpentier KP, Martin W, De Groot AS, et al. Aspartate-beta-hydroxylase (ASPH) induces epitope-specific T cell responses in hepatocellular carcinoma. Vaccine 2015;33:1256–66.

[40] Downing AK, Knott V, Werner JM, Cardy CM, Campbell ID, Handford PA. Solution structure of a pair of calcium-binding epidermal growth factor-like domains: implications for the Marfan syndrome and other genetic disorders. Cell 1996;85:597–605.

[41] Sterfljo J. Structure-function relationships of epidermal growth factor modules in vitamin K-dependent clotting factors. Blood 1991;78:1637–51.

[42] Blaheta RA, Kronenberg B, Witzasche D, Aath MK, Schulz M, Weber S, et al. De-differentiation of human hepatocytes by extracellular matrix proteins in vitro: quantitative and qualitative investigation of cytokeratin 7, 8, 18, 19 and vimentin filaments. J Hepatol 1998;28:877–90.

[43] Burgstaller G, Gregor M, Winter L, Wiche G. Keeping the vimentin network under control: cell-matrix adhesion-associated plectin 1f affects cell shape and polarity of fibroblasts. Mol Biol Cell 2010;21:3362–75.

[44] Kim H, Nakamura F, Lee W, Shifrin Y, Arora P, Mcculloch CA. Fileamin A is required for vimentin-mediated cell adhesion and spreading. Am J Physiol Cell Physiol 2010;298:C221–36.